In: NEOPLASMA, vol. 53, no. 5
S.y. Kang - Y.t. Oh - J.h. Han - J.-H. Choi - H.-Y. Lim - H.i. Kim - H.-W. Lee - J.h. Jang - J.s. Park - H.c. Kim - S. Kang - M. Chun - C.h. Kim - H.j. Joo
Detaily:
Rok, strany: 2006, 450 - 456
O článku:
A randomized trial has demonstrated that concurrent
chemoradiotherapy (CRT) is superior to radiotherapy (RT) alone in
locally advanced nasopharyngeal cancer (NPC).
Our study comprise 35 patients with locally advanced NPC (stage I:
1, II: 12, III: 7, IV: 15) with 1 cycle of induction chemotherapy
(5-fluorouracil 1,000 mg/m2/day and cisplatin 20 mg/m2/day, days 1—
4) followed by concurrent CRT starting on
day 22. Concurrent CRT consisted of RT (70 Gy/35 fractions for 7
weeks) with cisplatin 20 mg/m2/day for 4 days on weeks
1, 4, 7 of RT.
Complete response (CR) was achieved in 33 patients (94%). Four-year progression-free survival (PFS) and overall survival
(OS) of all patients were 57% and 65%, respectively. In analysis
of prognostic factors, low expression of bax was the
most significant independent predictor of poor prognosis in both
PFS (p=0.002) and OS (p=0.008).
In conclusion, the outcome of patients treated with this combined
therapeutical modality appears to be comparable with
that of Intergroup 0099 trial with high CR rate. Low expression of
bax was significantly associated with poor PFS and OS.
Ako citovať:
ISO 690:
Kang, S., Oh, Y., Han, J., Choi, J., Lim, H., Kim, H., Lee, H., Jang, J., Park, J., Kim, H., Kang, S., Chun, M., Kim, C., Joo, H. 2006. Concurrent chemoradiotherapy in patients with nasopharyngeal
cancer: prognostic significance of low expression of bax. In NEOPLASMA, vol. 53, no.5, pp. 450-456. 0028-2685.
APA:
Kang, S., Oh, Y., Han, J., Choi, J., Lim, H., Kim, H., Lee, H., Jang, J., Park, J., Kim, H., Kang, S., Chun, M., Kim, C., Joo, H. (2006). Concurrent chemoradiotherapy in patients with nasopharyngeal
cancer: prognostic significance of low expression of bax. NEOPLASMA, 53(5), 450-456. 0028-2685.